In the IMbrave-150 trial, patients with atezolizumab (a PD-L1 inhibitor) plus bevacizumab (a VEGF blockade) had an ORR of 30% and a median OS of 19.2 months, and the combination therapy also exhibited good efficacy for HCC patients in South Korea in the real world [180, 181]. This evidence concerns the gene CD274 and hepatocellular carcinoma.